Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,568.00-0.32%ETH$2,698.23-0.59%GOLD$4,192.00+0.12%OIL$90.07+0.70%
Smart Investors Daily
SID Premium
CR

NASDAQ · CRVS

Corvus Pharmaceuticals, Inc.

Healthcare · Biotechnology

$10.74

Down-$0.18 (-1.68%)

Updated Oct 7, 2026, 12:15 AM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
627.78M
P/E ratio
-46.21
Dividend yield
0.00%
52-week range
$6.39 – $26.95
Volume
825.39K
Avg. volume
1.02M

Price performance · CRVS

CRVS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

CRVS closed at $10.74 after 20 trading sessions, down 22.90% for the selected period.

Last close
$10.74
Period change
-22.90%
Period low
$10.74
Period high
$13.93
Daily close
View OHLC price history
CRVS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$10.88$11.145$10.45$10.74825.39K
Oct 2, 2026$11.11$11.11$10.64$10.901.35M
Oct 1, 2026$11.56$11.75$10.89$10.931.31M
Sep 30, 2026$11.995$12.03$11.50$11.52875.85K
Sep 29, 2026$12.365$12.42$11.72$11.76881.95K
Sep 28, 2026$11.66$12.12$11.25$11.871.21M
Sep 25, 2026$11.92$12.04$11.415$11.621.1M
Sep 24, 2026$12.46$12.475$11.505$11.801.14M
Sep 23, 2026$13.30$13.4469$12.245$12.54946.68K
Sep 22, 2026$12.55$13.46$12.35$13.44806.63K
Sep 21, 2026$12.80$12.80$12.275$12.42939.79K
Sep 18, 2026$12.53$12.61$12.25$12.564.46M
Sep 17, 2026$12.55$12.82$12.425$12.551.53M
Sep 16, 2026$13.00$13.145$12.18$12.23952.27K
Sep 15, 2026$13.07$13.17$12.45$12.951.4M
Sep 14, 2026$12.92$13.305$12.905$13.111.09M
Sep 11, 2026$13.13$13.495$12.7702$12.911.26M
Sep 10, 2026$13.06$13.135$12.82$12.941.09M
Sep 9, 2026$13.76$13.905$12.95$13.331.11M
Sep 8, 2026$14.01$14.32$13.85$13.931.03M

Latest CRVS news

The latest Smart Investors Daily articles mentioning CRVS.

Stock researchCompany · Overview

CRVS research

Overview

Company profile and research snapshot.

Company profile

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$14.50
Implied upside
—
Analysts
—
CRVS recent ratings
DateFirmRatingTarget
Apr 17, 2026Goldman SachsBuy—
Mar 13, 2026OppenheimerOutperform—
Jan 22, 2026JefferiesBuy—
Jan 21, 2026OppenheimerOutperform—
Jan 21, 2026BarclaysOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 23, 2026

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at Oppenheimer 36th Annual Healthcare Life Sciences Conference which is being held virtually. The presentation will be on Thursday, February 26, 2026 at 2:40pm ET. A webcast of the presentation will be available liv

Yahoo · Feb 17, 2026

Is Corvus Pharmaceuticals (CRVS) Still Attractive After Its Recent Share Price Surge

If you are wondering whether Corvus Pharmaceuticals' recent share price puts it on your watchlist or your worry list, you are not alone. The stock last closed at US$18.66 after a 131.8% return over 30 days, a 154.9% return year to date, a 282.4% return over 1 year and a very large 3 year return, followed by a 7 day return of an 8.6% decline. Recent coverage has focused on Corvus Pharmaceuticals as a high risk, high potential biotech name, with attention on its pipeline and clinical progress...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By